Industries
Multi-Omics and Systems Biology
Multi-omics research integrates genomics, transcriptomics, proteomics, metabolomics, and epigenomics data to construct a systems-level understanding of biological processes, disease mechanisms, and drug responses that no single data type can capture alone. Platforms from 10x Genomics, Olink Proteomics, Metabolon, Bruker, and Agilent Technologies enable researchers to profile the same sample across molecular layers, then apply network analysis, machine learning, and pathway enrichment to identify causal molecular drivers. Scientists procure multi-analyte sequencing libraries, proximity extension assay kits, untargeted mass spectrometry metabolomics services, and cloud-based bioinformatics integration suites. The convergence of spatial transcriptomics, single-cell proteomics, and long-read sequencing is expanding the resolution of multi-omics studies to subcellular compartments. Regulatory agencies are increasingly accepting multi-omics biomarker evidence for drug approvals, making the field critical infrastructure for both academic discovery and pharmaceutical development pipelines.
Details
- Companies
- 10x GenomicsOlink ProteomicsMetabolonBrukerAgilent TechnologiesQIAGENBiogazelle
- Market Size
- $4.1 billion (2024), projected $12.8 billion by 2030 at 21.4% CAGR
- Target Researchers
- Systems biologists, translational researchers, bioinformaticians, functional genomicists, and molecular epidemiologists integrating multi-layer molecular data.
- Use Cases
- Integrative genomics-proteomics-metabolomics profilingSingle-cell multi-omics landscape mappingDrug mechanism-of-action deconvolutionDisease biomarker discovery across molecular layersPathway network reconstruction and modelingCRISPR screen integration with transcriptomic readoutsLongitudinal biological aging clocks